This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guo, Z. Articles by Sidransky, D. Search for Related Content PubMed PubMed Citation Articles by Guo, Z. Articles by Sidransky, D.

Allelic Losses in OraTest-directed Biopsies of Patients with Prior Upper Aerodigestive Tract Malignancy¹

Department of Otolaryngology, Division of Head and Neck Cancer Research [Z. G., K. Y., M. S-C., W. M. K., D. S.], and Department of Pathology [W. H. W.], Johns Hopkins University, Baltimore, Maryland 21205-2196

Genetic alterations at critical chromosome loci have been shown to be predictors of the progression of oral premalignancy-to-invasive cancer. We obtained a unique group of oral biopsies, initially collected during a prospective study designed to test the ability of OraTest (toluidine blue), to identify recurrent oral neoplastic lesions in patients with definite therapy for head and neck or upper aerodigestive tract (UADT) cancer. A total of 46 cases, including 13 squamous cell carcinoma (SCC), 11 carcinoma-in situ or dysplasia, and 22 morphologically normal oral biopsies, were analyzed for loss of heterozygosity (LOH) at 9p21, 3p21, and 17p13(TP53) by microsatellite analysis. LOH at one or more tested markers in at least one biopsy was detected in 76% (35 of 46) cases. All of the SCC and carcinoma-in situ cases showed LOH, and, strikingly, more than one-half (69%, 13 of 22) of morphologically normal epithelia also harbored LOH in at least one tested marker. The most frequent LOH was found on chromosome 9p21 (69%, 31 of 45). LOH was observed at 3p21, 17p13(TP53), or in multiple chromosomal arms significantly more often in SCC than in normal epithelia. In the majority of cases, two oral biopsies, one from an OraTest-staining positive area and another from a negative area adjacent to the stain, were collected. Among 25 LOH positive cases with two biopsies, identical allelic losses were confirmed between stained and nonstained biopsies in 16 cases. In the remaining nine cases with discordant LOH patterns between two biopsies, eight cases showed LOH at more genetic loci in OraTest-stained areas. Our data confirm that clonal genetic alterations, especially 9p21 deletion, are often present in the oral epithelia of patients with previous UADT malignancy and, combined with previous studies, suggest that genetic analysis will help stratify patients at risk of developing a secondary oral cancer. In addition to detecting cancer, our study suggests that OraTest can detect clinically occult lesions in the progression pathway to oral cancer.

This article has been cited by other articles:

				L. L. Patton, J. B. Epstein, and A. R. Kerr Adjunctive Techniques for Oral Cancer Examination and Lesion Diagnosis: A Systematic Review of the Literature J Am Dent Assoc, July 1, 2008; 139(7): 896 - 905. [Abstract] [Full Text] [PDF]

				J. B. Epstein, M. Gorsky, D. Fischer, A. Gupta, M. Epstein, and S. Elad A Survey of the Current Approaches to Diagnosis and Management of Oral Premalignant Lesions J Am Dent Assoc, December 1, 2007; 138(12): 1555 - 1562. [Abstract] [Full Text] [PDF]

				D. Z. J. Chu, G. Gibson, D. David, and Y. Yen The Surgeon's Role in Cancer Prevention. The Model in Colorectal Carcinoma Ann. Surg. Oncol., November 1, 2007; 14(11): 3054 - 3069. [Abstract] [Full Text] [PDF]

				W. H. Westra and D. Sidransky Fluorescence Visualization in Oral Neoplasia: Shedding Light on an Old Problem. Clin. Cancer Res., November 15, 2006; 12(22): 6594 - 6597. [Full Text] [PDF]

				L. Zhang, M. Williams, C. F. Poh, D. Laronde, J. B. Epstein, S. Durham, H. Nakamura, K. Berean, A. Hovan, N. D. Le, et al. Toluidine Blue Staining Identifies High-Risk Primary Oral Premalignant Lesions with Poor Outcome Cancer Res., September 1, 2005; 65(17): 8017 - 8021. [Abstract] [Full Text] [PDF]

				S. M. Lippman, J. Sudbo, and W. K. Hong Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development J. Clin. Oncol., January 10, 2005; 23(2): 346 - 356. [Abstract] [Full Text] [PDF]

				B. J. M. Braakhuis, C. R. Leemans, R. H. Brakenhoff, M. P. Rosin, W. L. Lam, and L. Zhang Correspondence re: M. P. Rosin et al., 3p14 and 9p21 Loss Is a Simple Tool for Predicting Second Oral Malignancy at Previously Treated Oral Cancer Sites. Cancer Res., 62: 6447-6450, 2002. Cancer Res., August 15, 2003; 63(16): 5167 - 5169. [Full Text] [PDF]

				B. J. M. Braakhuis, M. P. Tabor, J. A. Kummer, C. R. Leemans, and R. H. Brakenhoff A Genetic Explanation of Slaughter's Concept of Field Cancerization: Evidence and Clinical Implications Cancer Res., April 15, 2003; 63(8): 1727 - 1730. [Abstract] [Full Text] [PDF]

				M. P. Rosin, W. L. Lam, C. Poh, N. D. Le, R. J. Li, T. Zeng, R. Priddy, and L. Zhang 3p14 and 9p21 Loss Is a Simple Tool for Predicting Second Oral Malignancy at Previously Treated Oral Cancer Sites Cancer Res., November 15, 2002; 62(22): 6447 - 6450. [Abstract] [Full Text] [PDF]

				L. A. Kresty, S. R. Mallery, T. J. Knobloch, H. Song, M. Lloyd, B. C. Casto, and C. M. Weghorst Alterations of p16INK4a and p14ARF in Patients with Severe Oral Epithelial Dysplasia Cancer Res., September 15, 2002; 62(18): 5295 - 5300. [Abstract] [Full Text] [PDF]